Platt Andrew P, Bradley Benjamin T, Nasir Nadia, Stein Sydney R, Ramelli Sabrina C, Ramos-Benitez Marcos J, Dickey James M, Purcell Madeleine, Singireddy Shreya, Hays Nicole, Wu Jocelyn, Raja Katherine, Curto Ryan, Salipante Stephen J, Chisholm Claire, Carnes Stephanie, Marshall Desiree A, Cookson Brad T, Vannella Kevin M, Madathil Ronson J, Soherwardi Shahabuddin, McCurdy Michael T, Saharia Kapil K, Rabin Joseph, Grazioli Alison, Kleiner David E, Hewitt Stephen M, Lieberman Joshua A, Chertow Daniel S
Emerging Pathogens Section, Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA.
Laboratory of Virology, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
Pathogens. 2023 Jul 12;12(7):932. doi: 10.3390/pathogens12070932.
Bacterial and fungal co-infections are reported complications of coronavirus disease 2019 (COVID-19) in critically ill patients but may go unrecognized premortem due to diagnostic limitations. We compared the premortem with the postmortem detection of pulmonary co-infections in 55 fatal COVID-19 cases from March 2020 to March 2021. The concordance in the premortem versus the postmortem diagnoses and the pathogen identification were evaluated. Premortem pulmonary co-infections were extracted from medical charts while applying standard diagnostic definitions. Postmortem co-infection was defined by compatible lung histopathology with or without the detection of an organism in tissue by bacterial or fungal staining, or polymerase chain reaction (PCR) with broad-range bacterial and fungal primers. Pulmonary co-infection was detected premortem in significantly fewer cases (15/55, 27%) than were detected postmortem (36/55, 65%; < 0.0001). Among cases in which co-infection was detected postmortem by histopathology, an organism was identified in 27/36 (75%) of cases. , , and were the most frequently identified bacteria both premortem and postmortem. Invasive pulmonary fungal infection was detected in five cases postmortem, but in no cases premortem. According to the univariate analyses, the patients with undiagnosed pulmonary co-infection had significantly shorter hospital ( = 0.0012) and intensive care unit ( = 0.0006) stays and significantly fewer extra-pulmonary infections ( = 0.0021). Bacterial and fungal pulmonary co-infection are under-recognized complications in critically ill patients with COVID-19.
细菌和真菌合并感染是危重症2019冠状病毒病(COVID-19)患者的并发症,但由于诊断局限性,生前可能未被识别。我们比较了2020年3月至2021年3月期间55例COVID-19死亡病例生前与死后肺部合并感染的检测情况。评估了生前与死后诊断及病原体鉴定的一致性。生前肺部合并感染根据标准诊断定义从病历中提取。死后合并感染定义为符合肺部组织病理学表现,无论是否通过细菌或真菌染色、或使用广谱细菌和真菌引物的聚合酶链反应(PCR)在组织中检测到病原体。生前检测到肺部合并感染的病例明显少于死后(15/55,27% 对比36/55,65%;<0.0001)。在死后通过组织病理学检测到合并感染的病例中,27/36(75%)的病例鉴定出了病原体。生前和死后最常鉴定出的细菌均为 、 和 。死后在5例中检测到侵袭性肺部真菌感染,但生前均未检测到。根据单因素分析,未诊断出肺部合并感染的患者住院时间(=0.0012)和重症监护病房停留时间(=0.0006)显著缩短,肺外感染显著减少(=